322 related articles for article (PubMed ID: 29452863)
1. Chest wall toxicity after hypofractionated proton beam therapy for liver malignancies.
Yeung R; Bowen SR; Chapman TR; MacLennan GT; Apisarnthanarax S
Pract Radiat Oncol; 2018; 8(4):287-293. PubMed ID: 29452863
[TBL] [Abstract][Full Text] [Related]
2. Dose-volume histogram analysis for risk factors of radiation-induced rib fracture after hypofractionated proton beam therapy for hepatocellular carcinoma.
Kanemoto A; Mizumoto M; Okumura T; Takahashi H; Hashimoto T; Oshiro Y; Fukumitsu N; Moritake T; Tsuboi K; Sakae T; Sakurai H
Acta Oncol; 2013 Apr; 52(3):538-44. PubMed ID: 22950386
[TBL] [Abstract][Full Text] [Related]
3. Effect of Tumor Location and Dosimetric Predictors for Chest Wall Toxicity in Single-Fraction Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer.
Manyam BV; Videtic GMM; Verdecchia K; Reddy CA; Woody NM; Stephans KL
Pract Radiat Oncol; 2019 Mar; 9(2):e187-e195. PubMed ID: 30529796
[TBL] [Abstract][Full Text] [Related]
4. Incidence and predictors of chest wall toxicity after high-dose radiation therapy in 15 fractions.
Swanick CW; Allen PK; Tao R; Olanrewaju AM; Sutton JR; Lin SH; Welsh J; Das P; Chang JY; Crane CH; Gomez DR
Pract Radiat Oncol; 2017; 7(1):63-71. PubMed ID: 27637136
[TBL] [Abstract][Full Text] [Related]
5. Hypofractionated proton beam radiotherapy in patients with unresectable liver tumors: multi-institutional prospective results from the Proton Collaborative Group.
Parzen JS; Hartsell W; Chang J; Apisarnthanarax S; Molitoris J; Durci M; Tsai H; Urbanic J; Ashman J; Vargas C; Stevens C; Kabolizadeh P
Radiat Oncol; 2020 Nov; 15(1):255. PubMed ID: 33148296
[TBL] [Abstract][Full Text] [Related]
6. Proton Beam Therapy in Liver Malignancies.
Siddiqui O; Pollock A; Samanta S; Kaiser A; Molitoris JK
Curr Oncol Rep; 2020 Feb; 22(3):30. PubMed ID: 32108284
[TBL] [Abstract][Full Text] [Related]
7. Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.
Hong TS; Wo JY; Yeap BY; Ben-Josef E; McDonnell EI; Blaszkowsky LS; Kwak EL; Allen JN; Clark JW; Goyal L; Murphy JE; Javle MM; Wolfgang JA; Drapek LC; Arellano RS; Mamon HJ; Mullen JT; Yoon SS; Tanabe KK; Ferrone CR; Ryan DP; DeLaney TF; Crane CH; Zhu AX
J Clin Oncol; 2016 Feb; 34(5):460-8. PubMed ID: 26668346
[TBL] [Abstract][Full Text] [Related]
8. Chest wall volume receiving >30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy.
Dunlap NE; Cai J; Biedermann GB; Yang W; Benedict SH; Sheng K; Schefter TE; Kavanagh BD; Larner JM
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):796-801. PubMed ID: 19427740
[TBL] [Abstract][Full Text] [Related]
9. Dose-volume parameters predict for the development of chest wall pain after stereotactic body radiation for lung cancer.
Mutter RW; Liu F; Abreu A; Yorke E; Jackson A; Rosenzweig KE
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1783-90. PubMed ID: 21868173
[TBL] [Abstract][Full Text] [Related]
10. Characterization of Chest Wall Toxicity During Long-term Follow Up After Thoracic Stereotactic Body Radiation Therapy.
Chipko C; Ojwang J; Gharai LR; Deng X; Mukhopadhyay N; Weiss E
Pract Radiat Oncol; 2019 May; 9(3):e338-e346. PubMed ID: 30731275
[TBL] [Abstract][Full Text] [Related]
11. Hypofractionated Radiation Therapy for Unresectable/Locally Recurrent Intrahepatic Cholangiocarcinoma.
Smart AC; Goyal L; Horick N; Petkovska N; Zhu AX; Ferrone CR; Tanabe KK; Allen JN; Drapek LC; Qadan M; Murphy JE; Eyler CE; Ryan DP; Hong TS; Wo JY
Ann Surg Oncol; 2020 Apr; 27(4):1122-1129. PubMed ID: 31873931
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes and toxicity of proton beam therapy for advanced cholangiocarcinoma.
Makita C; Nakamura T; Takada A; Takayama K; Suzuki M; Ishikawa Y; Azami Y; Kato T; Tsukiyama I; Kikuchi Y; Hareyama M; Murakami M; Fuwa N; Hata M; Inoue T
Radiat Oncol; 2014 Jan; 9():26. PubMed ID: 24422711
[TBL] [Abstract][Full Text] [Related]
13. Predictors of toxicity associated with stereotactic body radiation therapy to the central hepatobiliary tract.
Osmundson EC; Wu Y; Luxton G; Bazan JG; Koong AC; Chang DT
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):986-94. PubMed ID: 25659885
[TBL] [Abstract][Full Text] [Related]
14. Predictors of Radiation-Induced Liver Disease in Eastern and Western Patients With Hepatocellular Carcinoma Undergoing Proton Beam Therapy.
Hsieh CE; Venkatesulu BP; Lee CH; Hung SP; Wong PF; Aithala SP; Kim BK; Rao A; Tung-Chieh Chang J; Tsang NM; Wang CC; Lee CC; Lin CC; Tseng JH; Chou WC; Wang YC; Krishnan S; Hong JH
Int J Radiat Oncol Biol Phys; 2019 Sep; 105(1):73-86. PubMed ID: 30797890
[TBL] [Abstract][Full Text] [Related]
15. Proton beam therapy for hepatocellular carcinoma.
Yeung RH; Chapman TR; Bowen SR; Apisarnthanarax S
Expert Rev Anticancer Ther; 2017 Oct; 17(10):911-924. PubMed ID: 28825506
[TBL] [Abstract][Full Text] [Related]
16. Analysis of repeated proton beam therapy for patients with hepatocellular carcinoma.
Oshiro Y; Mizumoto M; Okumura T; Fukuda K; Fukumitsu N; Abei M; Ishikawa H; Takizawa D; Sakurai H
Radiother Oncol; 2017 May; 123(2):240-245. PubMed ID: 28366501
[TBL] [Abstract][Full Text] [Related]
17. Corneal Substructure Dosimetry Predicts Corneal Toxicity in Patients With Uveal Melanoma Treated With Proton Beam Therapy.
Lee HJ; Stacey A; Klesert TR; Wells C; Skalet AH; Bloch C; Fung A; Bowen SR; Wong TP; Shibata D; Halasz LM; Rengan R
Int J Radiat Oncol Biol Phys; 2019 Jun; 104(2):374-382. PubMed ID: 30763658
[TBL] [Abstract][Full Text] [Related]
18. Dosimetric Factors and Toxicity in Highly Conformal Thoracic Reirradiation.
Binkley MS; Hiniker SM; Chaudhuri A; Maxim PG; Diehn M; Loo BW; Shultz DB
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):808-15. PubMed ID: 26831903
[TBL] [Abstract][Full Text] [Related]
19. Clinical Outcomes of Patients With Recurrent Lung Cancer Reirradiated With Proton Therapy on the Proton Collaborative Group and University of Florida Proton Therapy Institute Prospective Registry Studies.
Badiyan SN; Rutenberg MS; Hoppe BS; Mohindra P; Larson G; Hartsell WF; Tsai H; Zeng J; Rengan R; Glass E; Katz S; Vargas C; Feigenberg SJ; Simone CB
Pract Radiat Oncol; 2019; 9(4):280-288. PubMed ID: 30802618
[TBL] [Abstract][Full Text] [Related]
20. A dosimetric parameter to limit chest wall toxicity in SABR of NSCLC.
Jumeau R; Filion É; Bahig H; Vu T; Lambert L; Roberge D; Doucet R; Campeau MP
Br J Radiol; 2017 Jul; 90(1075):20170196. PubMed ID: 28590814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
